Feb 19, 2026 05:31PM
Feb 17, 2026 07:00AM
Feb 16, 2026 05:31PM
Feb 10, 2026 07:01AM
Feb 10, 2026 07:00AM
Dec 16, 2025 07:30AM
Dec 16, 2025 07:30AM REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata
Nov 8, 2025 05:45PM
Nov 6, 2025 04:15PM
Oct 22, 2025 08:00AM
Sep 18, 2025 08:46AM
Sep 18, 2025 08:45AM
Sep 9, 2025 07:00AM
Aug 7, 2025 04:15PM Nektar Therapeutics Reports Second Quarter 2025 Financial Results
Jul 29, 2025 09:01AM
Jul 29, 2025 09:00AM
Jun 24, 2025 07:31AM
Jun 24, 2025 07:30AM
May 8, 2025 04:15PM
Mar 12, 2025 04:15PM
Feb 26, 2025 07:01AM Nektar Therapeutics (NKTR) Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin
Feb 26, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 24, 2025 07:00AM
Feb 10, 2025 07:01AM
Feb 10, 2025 07:00AM
Dec 7, 2024 12:00PM Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeti
Nov 4, 2024 08:30AM
Nov 4, 2024 08:30AM
Mar 19, 2024 04:15PM
Jan 22, 2024 08:23AM
Dec 12, 2022 10:05AM
Apr 29, 2022 06:59AM
Apr 14, 2022 04:33PM Nektar Therapeutics (NKTR) and Bristol Myers Squibb (BMY) End Bempegaldesleukin in Combination with Opdivo Program
Apr 14, 2022 04:30PM
Mar 15, 2022 06:37AM
Mar 14, 2022 07:00AM
Mar 14, 2022 06:59AM
Sep 21, 2021 09:00AM
Nov 11, 2020 02:00PM
Oct 27, 2020 07:34AM Nektar Therapeutics (NKTR) Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
Oct 27, 2020 07:30AM
Feb 27, 2020 04:15PM
Feb 12, 2020 10:39AM
Feb 3, 2020 09:23AM
Jan 15, 2020 09:17AM
Jan 15, 2020 06:12AM
Jan 14, 2020 10:47PM Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
Jan 14, 2020 05:31PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All